ReviewNature immunology2026
Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis.
Review in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic interstitial lung disease with significant unmet need, and only a few therapeutic options slow decline rather than improve function. An expanding fibrotic niche is one hallmark of this disease, comprising a multicellular environment characterized by epithelial dysfunction and death, infiltration of peripheral immune cells, differentiation of fibroblasts and immune cells, extracellular matrix turnover and deposition of fibrillar collagen. Inflammation is a master regulator spanning all aspects of this fibrotic niche through cellular players and signaling mediators that can be split into three primary types. In many immune responses, the inflammatory milieu is dominated by one type of inflammation at a time, but recent findings suggest there might be more spatial and kinetic overlap present in fibrotic diseases, including IPF, than previously appreciated. In this Review, we summarize some of the key cellular players and soluble mediators involved in IPF progression and how distinct types of inflammation jointly regulate disease progression in concert rather than focus on individual cytokines or immune cells.
Indexed as
Identifiers
42629416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.